Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vimta LabsBOM:524394 +3.58%84 PB Ratio is 6.27 as of Aug. 05, 2026, which is 102% above its 10-year median of 3.11. GuruFocus rates BOM:524394 with a GF Score™ of 84/100 and a GF Value™ of ₹495.16 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 195 Medical Diagnostics & Research companies, Vimta Labs ranks worse than 82.05% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-08-05), Vimta Labs's share price is ₹641.20. Vimta Labs's Book Value per Share for the quarter that ended in Jun. 2026 was ₹102.28. Hence, Vimta Labs's PB Ratio of today is 6.27.
The historical rank and industry rank for Vimta Labs's PB Ratio or its related term are showing as below:
BOM:524394'
s PB Ratio Range Over the Past 10 Years
Min: 0.77 Med: 3.11 Max: 7.91
Current: 5.87
During the past 13 years, Vimta Labs's highest PB Ratio was 7.91. The lowest was 0.77. And the median was 3.11.
BOM:524394's PB Ratio is ranked worse than 82.05% of 195
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.09
vs BOM:524394: 5.87
During the past 12 months, Vimta Labs's average Book Value Per Share Growth Rate was 20.10% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 17.10% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 17.90% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 13.50% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Vimta Labs was 17.60% per year. The lowest was -5.50% per year. And the median was 7.90% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Vimta Labs PB Ratio Related Terms
Vimta Labs PB Ratio Historical Data
* Premium members only.
The historical data trend for Vimta Labs's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Vimta Labs's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vimta Labs PB Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Vimta Labs's PB Ratio distribution charts can be found below:
* The bar in red indicates where Vimta Labs's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Vimta Labs's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Vimta Labs (BOM:524394) has a PB Ratio of 6.27 as of Aug. 05, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Vimta Labs and its competitors. This is 102% above median its historical median of 3.11. Over the past decade, Vimta Labs' PB Ratio has ranged from 0.77 to 7.91. According to the industry distribution chart, Vimta Labs ranks #160 out of 195 companies in the Medical Diagnostics & Research industry, placing it in the top 82.1%.
Is Vimta Labs' PB Ratio too high?
Vimta Labs' current PB Ratio of 6.27 is 102% above median its 10-year median of 3.11. Over the past 10 years, this metric has ranged from a low of 0.77 to a high of 7.91. The Medical Diagnostics & Research industry median PB Ratio is 2.09. Vimta Labs' value of 6.27 is 200% above this industry median. Based on the distribution chart, Vimta Labs ranks #160 out of 195 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Vimta Labs has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vimta Labs' PB Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Vimta Labs ranks #160 out of 195 companies for PB Ratio. This places Vimta Labs in the lower half of its industry. The industry median PB Ratio is 2.09. Vimta Labs' value of 6.27 is 200% above this benchmark. Historically, Vimta Labs' own PB Ratio has ranged from 0.77 to 7.91 over the past decade. While the company's 10-year median is 3.11 vs. the industry median of 2.09, Vimta Labs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Diagnostics & Research company?
The median PB Ratio among Medical Diagnostics & Research companies is 2.09, based on 195 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vimta Labs's current PB Ratio of 6.27 is 200% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Vimta Labs and its competitors. For the Medical Diagnostics & Research industry, the median PB Ratio is 2.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vimta Labs's current PB Ratio is 6.27, which is 102% above median its own 10-year median of 3.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vimta Labs stock overvalued right now?
Based on GuruFocus' analysis, Vimta Labs (BOM:524394) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹495.16, compared to a current price of ₹641.20 — trading 29.5% above its estimated fair value. The current PB Ratio is 6.27, which is 102% above median its 10-year median of 3.11 and 200% above the Medical Diagnostics & Research industry median of 2.09. Vimta Labs' overall GF Score™ is 84/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Vimta Labs (BOM:524394), the current PB Ratio is 6.27 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vimta Labs (BOM:524394) Overvalued in 2026?
Based on GuruFocus' analysis, Vimta Labs stock appears to be overvalued.
The current stock price of ₹641.20 is trading 29.5% above its estimated GF Value™ of ₹495.16.
GuruFocus considers Vimta Labs to be Modestly Overvalued.
Key valuation signals for BOM:524394:
PB Ratio: 6.27 (102% above median its 10-year median of 3.11)
GF Value™: ₹495.16 vs. price of ₹641.20 (29.5% above fair value)
Industry Position: 200% above the Medical Diagnostics & Research median (#160 of 195)
No single metric tells the full story. See the BOM:524394 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vimta Labs Ltd is a comprehensive contract research and testing organization, providing a wide range of services to pharmaceutical, biopharmaceutical, food, consumer goods, electronic, electrical, agrochemical, healthcare, medical device, and many other industries. Its services portfolio includes testing and contract research services in the fields of clinical research, pre-clinical research, clinical diagnostics, biopharma services, analytical testing, research and environmental studies, and Others. It has only one reportable segment namely Contract Research and Testing Services which generates the revenue.
84GF Score
Get the complete analysis for BOM:524394
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524394 has been successfully added to your 
